Clinical Significance of the Prealbumin Level in Gastric Cancer Patients Who Receive Curative Treatment

Overview

Journal J Gastrointest Cancer

Publisher Springer

Specialties Gastroenterology
Oncology

Date 2021 Dec 18

PMID 34921671

Citations 4

Authors

Toru Aoyama

Masato Nakazono

Kenki Segami

Shinsuke Nagasawa

Kazuki Kano

Kentaro Hara

Yukio Maezawa

Itaru Hashimoto

Hideaki Suematsu

Hayato Watanabe

Keisuke Komori

Hiroshi Tamagawa

Norio Yukawa

Yasushi Rino

Takashi Ogata

Takashi Oshima

Affiliations

Soon will be listed here.

Abstract

Background: We investigated the clinical influence of the prealbumin level on the gastric cancer survival and recurrence after curative treatment.

Methods: This study included 447 patients who underwent curative treatment for gastric cancer between 2013 and 2017. The risk factors for the overall survival (OS) and recurrence-free survival (RFS) were identified.

Results: A prealbumin level of 20 mg/dl was regarded as the optimal point of classification, considering the 3- and 5-year survival rates. The OS rates at 3 and 5 years after surgery were 80.7% and 65.0% in the low-prealbumin group, respectively, and 93.1% and 87.9% in the high-prealbumin group, respectively, a statistically significant difference (p < 0.001). The RFS rates at 3 and 5 years after surgery were 71.7% and 68.0% in the low-prealbumin group, respectively, and 90.1% and 84.7% in the high-prealbumin group, respectively, a statistically significant difference (p = 0.031). A multivariate analysis demonstrated that the prealbumin level was a significant independent risk factor for the OS and RFS. In addition, the rate of introduction of adjuvant chemotherapy was significantly lower and the frequency of peritoneal recurrence and lymph node recurrence significantly higher in the low-prealbumin group than in the high-prealbumin group.

Conclusion: Prealbumin is a risk factor for the survival in patients who undergo curative treatment for gastric cancer. It is necessary to develop an effective plan of perioperative care and surgical strategy according to the prealbumin level.

Citing Articles

Development and validation of nomograms for predicting the prognosis of early and late recurrence of advanced gastric cancer after radical surgery based on post-recurrence survival.

Liu C, Lu J, An L Medicine (Baltimore). 2024; 103(22):e38376.

PMID: 39259073 PMC: 11142773. DOI: 10.1097/MD.0000000000038376.

Research progress on predictive models for malnutrition in cancer patients.

Zheng P, Wang B, Luo Y, Duan R, Feng T Front Nutr. 2024; 11:1438941.

PMID: 39234292 PMC: 11371767. DOI: 10.3389/fnut.2024.1438941.

Clinical Significance of Prealbumin Level Measurement Before Neoadjuvant Chemotherapy in Elderly Patients With Locally Advanced Esophageal Cancer.

Suematsu H, Yamada T, Onuma S, Hashimoto I, Kanematsu K, Nagasawa S In Vivo. 2023; 38(1):334-340.

PMID: 38148082 PMC: 10756447. DOI: 10.21873/invivo.13443.

Construction and validation of a predictive model for the risk of three-month-postoperative malnutrition in patients with gastric cancer: a retrospective case-control study.

Dai T, Wu D, Tang J, Liu Z, Zhang M J Gastrointest Oncol. 2023; 14(1):128-145.

PMID: 36915453 PMC: 10007955. DOI: 10.21037/jgo-22-1307.

References

Shen Q, Liu W, Quan H, Pan S, Li S, Zhou T . Prealbumin and lymphocyte-based prognostic score, a new tool for predicting long-term survival after curative resection of stage II/III gastric cancer. Br J Nutr. 2018; 120(12):1359-1369. DOI: 10.1017/S0007114518002854. View

Keller U . Nutritional Laboratory Markers in Malnutrition. J Clin Med. 2019; 8(6). PMC: 6616535. DOI: 10.3390/jcm8060775. View

. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011; 14(2):101-12. DOI: 10.1007/s10120-011-0041-5. View

Zhang X, Fang H, Zeng Z, Zhang K, Lin Z, Deng G . Preoperative Prognostic Nutrition Index as a Prognostic Indicator of Survival in Elderly Patients Undergoing Gastric Cancer Surgery. Cancer Manag Res. 2021; 13:5263-5273. PMC: 8259731. DOI: 10.2147/CMAR.S316437. View

Cai W, Kong W, Dong B, Zhang J, Chen Y, Xue W . Pretreatment Serum Prealbumin as an Independent Prognostic Indicator in Patients With Metastatic Renal Cell Carcinoma Using Tyrosine Kinase Inhibitors as First-Line Target Therapy. Clin Genitourin Cancer. 2017; 15(3):e437-e446. DOI: 10.1016/j.clgc.2017.01.008. View

Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A . Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007; 357(18):1810-20. DOI: 10.1056/NEJMoa072252. View

Kelly P, Paulin F, Lamont D, Baker L, Clearly S, Exon D . Pre-treatment plasma proteomic markers associated with survival in oesophageal cancer. Br J Cancer. 2012; 106(5):955-61. PMC: 3305965. DOI: 10.1038/bjc.2012.15. View

Pentheroudakis G . Recent eUpdates to the ESMO Clinical Practice Guidelines on hepatocellular carcinoma, cancer of the pancreas, soft tissue and visceral sarcomas, cancer of the prostate and gastric cancer. Ann Oncol. 2019; 30(8):1395-1397. DOI: 10.1093/annonc/mdz180. View

Han W, Chen Z, Wei Z, Xu A . Preoperative pre-albumin predicts prognosis of patients after gastrectomy for adenocarcinoma of esophagogastric junction. World J Surg Oncol. 2016; 14(1):279. PMC: 5094092. DOI: 10.1186/s12957-016-1035-x. View

10.

Kawai H, Ota H . Low perioperative serum prealbumin predicts early recurrence after curative pulmonary resection for non-small-cell lung cancer. World J Surg. 2012; 36(12):2853-7. DOI: 10.1007/s00268-012-1766-y. View

11.

Raiten D, Sakr Ashour F, Ross A, Meydani S, Dawson H, Stephensen C . Inflammation and Nutritional Science for Programs/Policies and Interpretation of Research Evidence (INSPIRE). J Nutr. 2015; 145(5):1039S-1108S. PMC: 4448820. DOI: 10.3945/jn.114.194571. View

12.

Wang N, Xi W, Lu S, Jiang J, Wang C, Zhu Z . A Novel Inflammatory-Nutritional Prognostic Scoring System for Stage III Gastric Cancer Patients With Radical Gastrectomy Followed by Adjuvant Chemotherapy. Front Oncol. 2021; 11:650562. PMC: 8238197. DOI: 10.3389/fonc.2021.650562. View

13.

Inoue H, Kosuga T, Kubota T, Konishi H, Shiozaki A, Okamoto K . Significance of a preoperative systemic immune-inflammation index as a predictor of postoperative survival outcomes in gastric cancer. World J Surg Oncol. 2021; 19(1):173. PMC: 8199826. DOI: 10.1186/s12957-021-02286-3. View

14.

Shimoda Y, Fujikawa H, Komori K, Watanabe H, Kano K, Yamada T . Preoperative Utility of the Glasgow Prognostic Score on Outcomes of Patients with Locally Advanced Gastric Cancer. J Gastrointest Cancer. 2021; 53(2):265-271. DOI: 10.1007/s12029-021-00584-3. View

15.

Smyth E, Nilsson M, Grabsch H, van Grieken N, Lordick F . Gastric cancer. Lancet. 2020; 396(10251):635-648. DOI: 10.1016/S0140-6736(20)31288-5. View

16.

Muro K, Van Cutsem E, Narita Y, Pentheroudakis G, Baba E, Li J . Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol. 2018; 30(1):19-33. DOI: 10.1093/annonc/mdy502. View

17.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View